What are the key statistics and safety data for the Tdap (tetanus, diphtheria, and pertussis) vaccine that should be communicated to pregnant patients?

Key Statistics and Safety Data for Tdap Vaccination in Pregnancy

Tdap vaccination during pregnancy between 27-36 weeks gestation is 80-91% effective at preventing pertussis in infants younger than 2 months of age, with no increased risk of serious adverse events for mother or baby. 1, 2

Effectiveness Statistics to Share

Infant Protection:

• Maternal Tdap vaccination provides 80-91% effectiveness in preventing pertussis in infants before they can receive their own vaccinations 1
• Infants born to vaccinated mothers have significantly higher pertussis antibody levels at birth (68.8 EU/mL vs 14.0 EU/mL in unvaccinated) and at 2 months of age (20.6 EU/mL vs 5.3 EU/mL) 3
• Protection is highest when vaccine is given earlier in the 27-36 week window (27-32 weeks produces higher cord blood antibodies than after 32 weeks) 4
• Antibodies require at least 2 weeks after vaccination to reach maximal levels and transfer to the baby 4

Why Each Pregnancy Requires Vaccination:

• Pertussis antibodies wane substantially within the first year after vaccination 4
• Women vaccinated before or early in pregnancy have low antibody levels by delivery, insufficient to protect the infant 4

Safety Profile Statistics

Maternal Safety:

• No serious adverse events directly attributable to Tdap have been identified in pregnant women 3, 5
• Common injection site reactions occur in approximately 79% of pregnant women (pain, swelling, redness) 3
• Systemic symptoms (headache, malaise, myalgia) occur in approximately 36% of pregnant women 3
• Fever is rare, occurring in 3% or less of vaccinated pregnant women 5

Pregnancy and Birth Outcomes:

• No increased risk of preterm delivery (adjusted relative risk 0.71, meaning actually lower risk observed) 6
• No increased risk of low birth weight or small for gestational age infants 7, 6
• No increased risk of stillbirth or fetal death 5, 6
• No increased risk of congenital anomalies (point estimates ranged 0.47-1.50 across multiple studies, all confidence intervals crossed 1.0) 5
• A large study of 16,606 vaccinated pregnant women found no clinically significant increased risks for major maternal or infant outcomes 6

Infant Safety:

• No serious adverse events in infants born to vaccinated mothers 3
• Normal growth and development through 13 months of age 3
• No cases of pertussis occurred in infants of vaccinated mothers in clinical trials 3

Important Nuance About Infant Vaccine Response

Blunting Effect (Reassurance Needed):

• Infants born to vaccinated mothers show modestly reduced antibody responses (7-48% lower) to their own DTaP vaccines after the third dose 4
• However, after the fourth DTaP dose, antibody levels are comparable between infants of vaccinated and unvaccinated mothers 4
• The clinical significance is unknown because protective antibody levels for pertussis are not well-defined 4
• This theoretical concern is far outweighed by the proven benefit of preventing pertussis in the vulnerable first 2 months of life 4

Timing Optimization

Optimal Window:

• Vaccination between 27-36 weeks gestation maximizes maternal antibody response and passive transfer to infant 4
• Vaccinating earlier in this window (27-30 weeks) may produce higher infant antibody levels 4, 1
• Active antibody transport across the placenta does not substantially occur before 30 weeks 4

Common Pitfalls to Avoid

• Do not skip Tdap if the patient received it in a previous pregnancy—vaccination is required with every pregnancy 4
• Do not delay beyond 36 weeks—antibodies need time to develop and transfer 4
• Do not substitute postpartum vaccination for prenatal vaccination—this does not protect the infant during the highest-risk period 4
• Do not withhold due to recent Tdap—even if received within the past year, give again during pregnancy for optimal infant protection 4

Safety Monitoring Data

Large-Scale Surveillance:

• Tetanus toxoid-containing vaccines have been used extensively worldwide in pregnant women to prevent neonatal tetanus without clinically significant severe adverse events 4
• The Vaccine Safety Datalink and Vaccine Adverse Event Reporting System continue active monitoring with no safety signals identified 4
• Experience with tetanus-toxoid vaccines suggests no excess risk for severe adverse events with Tdap in every pregnancy 4